| |
All patientsa
|
Local recurrenceb
|
Locoregional recurrencec
|
Metastatic diseased
|
|---|
| | | | | | |
Regional nodal and metastatic lesions
|
Metastatic lesions alone
|
|---|
| |
n = 32
|
%
|
n = 7
|
%
|
n = 8
|
%
|
n = 13
|
%
|
n = 4
|
%
|
|---|
|
Median age at diagnosis
|
56.5 (range 52.5–73.7)
|
55.0 (range 53.0–61.5)
|
57.2 (range 53.1–69.4)
|
59.2 (range 53.0–73.7)
|
58.6 (range 52.5–66.8)
|
|
Tumor stage
| | | | | | | | | | |
|
T2
|
14
|
43.8%
|
5
|
62.5%
|
3
|
37.5%
|
3
|
23.1%
|
3
|
75.0%
|
|
T3a
|
8
|
25.0%
|
1
|
12.5%
|
4
|
50.0%
|
3
|
23.1%
|
0
|
0%
|
|
T3b
|
9
|
28.1%
|
1
|
12.5%
|
1
|
12.5%
|
6
|
46.2%
|
1
|
25.0%
|
|
T4
|
1
|
3.1%
|
0
|
0.0%
|
0
|
0.0%
|
1
|
7.7%
|
0
|
0%
|
|
Nodal stage
| | | | | | | | | | |
|
N0
|
26
|
81.3%
|
6
|
75.0%
|
7
|
87.5%
|
10
|
76.9%
|
3
|
75.0%
|
|
N1
|
1
|
3.1%
|
0
|
0.0%
|
0
|
0.0%
|
1
|
7.7%
|
0
|
0%
|
|
Nx
|
5
|
15.6%
|
1
|
12.5%
|
1
|
12.5%
|
2
|
15.4%
|
1
|
25.0%
|
|
Gleason score
| | | | | | | | | | |
|
6
|
2
|
6.3%
|
2
|
25.0%
|
0
|
0.0%
|
0
|
0%
|
0
|
0%
|
|
7 (3 + 4)
|
8
|
25.0%
|
2
|
25.0%
|
3
|
37.5%
|
1
|
7.7%
|
2
|
50.0%
|
|
7 (4 + 3)
|
11
|
34.4%
|
2
|
25.0%
|
1
|
12.5%
|
8
|
61.5%
|
0
|
0%
|
|
8
|
8
|
25.0%
|
1
|
12.5%
|
2
|
25.0%
|
4
|
30.8%
|
1
|
25.0%
|
|
9
|
3
|
9.4%
|
0
|
0.0%
|
2
|
25.0%
|
0
|
0%
|
1
|
25.0%
|
|
Positive surgical margins
|
13
|
40.6%
|
3
|
37.5%
|
3
|
37.5%
|
7
|
53.8%
|
0
|
0%
|
|
Median time to biochemical failure
|
30.1 mo (1.1–113.9)
|
30.5 mo (1.4–86.3)
|
27 mo (2.7–113.9)
|
15.8 mo (1.1–82.0)
|
49.9 mo (1.4–94.3)
|
|
Median PSA at 18F-PSMA PET
|
2.4 ng/mL (0.38–22.37)
|
1.3 ng/ml (0.5–3.3)
|
1.6 ng/ml (0.4–8.9)
|
4.8 ng/ml (1.3–22.4)
|
5.4 ng/ml (2.0–7.9)
|
- aAll 32 patients included in the analysis of those who received PORT after prostatectomy prior to mpMRI and PSMA PET/CT imaging as per inclusion criteria
- bSubgroup of the 32 patients with local recurrence alone on mpMRI and PSMA PET/CT
- cSubgroup of the 32 patients who were found to have regional nodal recurrence (± local) on mpMRI and PSMA PET/CT
- dSubgroup of the 32 patients who were found to have metastatic (± local or regional nodal) disease on mpMRI and PSMA PET/CT
